NCI, EPA Attempt to Resolve Differences Over Childhood Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BETHESDA, Md--Officials of the National Cancer Institute (NCI) and the Environmental Protection Agency (EPA) are attempting to resolve their conflicting interpretations of data regarding cancer in children. The NCI has forcefully challenged the EPA’s contention that the United States is in the midst of an epidemic of childhood malignancies.

BETHESDA, Md--Officials of the National Cancer Institute (NCI) and the Environmental Protection Agency (EPA) are attempting to resolve their conflicting interpretations of data regarding cancer in children. The NCI has forcefully challenged the EPA’s contention that the United States is in the midst of an epidemic of childhood malignancies.

An EPA conference last September declared that cancer in US children has increased steadily over the last quarter century and that the situation demands a focused program to determine the cause of the increase and find means of prevention. This led to a reassessment by NCI epidemiologists of data from the Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

Martha Linet, MD, who led the NCI review, said that her group found "no evidence of a consistent increase in the incidence during 1973 to 1994 for specific types of childhood cancer."

In late January, senior EPA and NCI officials met for more than 2 hours to discuss the childhood cancer data, Hugh W. McKinnon, MD, of EPA’s National Risk Management Research Laboratory in Cincinnati, reported at the NCAB February meeting. They agreed that staff scientists from the two agencies would hold further meetings to try to resolve the conflicting interpretation of the childhood cancer statistics.

"Honest scientists will have honest disagreements over data, and we are trying to understand that data," Dr. McKinnon told Oncology News International.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content